I think what the pharma expert Sajal sir said is true. It doesn’t make sense for any parties involved in the whole pharma value chain and hence not expected to materialise. As said before I have read these diktats since a long time. And we need to check the date of publication of these stuff and read in details who it is applicable to.
Having said that, I have felt since a long time that as of now pharma space is something that does not excite me too much. A lot of these companeis especially the US facing companies (where the actual big bucks can be made) are facing pricing heat. Domestic pharma market is highly fragmented it has its own set of problems. Plus finding a company with exclusive domestic presence is difficult. Most pharma companies have a business model wherein part of business comes from exports.
As seen in the past, bulk drugs, had a stellar run wherein stocks gave multibagger returns. But as of now that too seems to be a thing of the past, and while there can be a winner here or there within the sector, base rate of finding winners is low. So I prefer to focus elsewhere.
For those interested in knowing more about the pharma space, @gurjeev has put up a write up on Medicamen biotech on Shivalik rasayan thread . There he has tried to put up details of some terms people find difficult to understand while looking at pharma space. I have my doubts about my ability to project numbers mentioned in the report, but just as a report to understand a pharma company, one should read it.
Subscribe To Our Free Newsletter |